Moderna CEO Stéphane Bancel suggested that partnerships could be on the horizon depending on future sales figures. The company has built a largely wholly-owned pipeline thanks to revenue from the initial launch of its COVID vaccine.
Eli Lilly is in an “all of the above mode” in obesity, with the research teams moving as fast as possible to advance an oral candidate and build a portfolio of complimentary treatments.
Rani Therapeutics and Sangamo Therapeutics have become the latest biotechs to significantly shrink their workforces in order to eke out cash for another year.
Convert more DNA into sequenceable library for enhanced sensitivity — particularly with cfDNA samples and ctDNA detection. Prepare highly complex libraries in under 2 hours from as little as 500 pg. Explore the data.
The targeted IRAK4 protein degrader KT-413 did exactly what it was supposed to in an early-stage clinical trial, but Kymera Therapeutics is jettisoning the program.
Increasingly confident in the potential of its SMARCA2 degrader and a CDK9 inhibitor to treat cancers, Prelude Therapeutics is scrapping the other half of its clinical pipeline.
An antibiotic from the non-profit Global Antibiotic Research & Development Partnership (GARDP) and Innoviva Specialty Therapeutics has met the current standard-of-care for gonorrhea, hitting the main goal of a pivotal phase 3 trial.
Nurix Therapeutics has had a phase 1 trial of its B-cell malignancy drug put on partial hold by the FDA while the biotech revamps its manufacturing process.
Medeor Therapeutics’ kidney transplant cell therapy, which combines a living donor’s cells with the recipient's, allowed more than half of study participants in a phase 3 pivotal trial to stay off immunosuppressants for two years.
Resolian, which rebranded from Alliance Pharma earlier this year, expanded its services with the acquisition of China-based bioanalytical CRO Denali Medpharma for an undisclosed price.
As strong demand continues to push Mounjaro sales to new highs, Eli Lilly CEO David Ricks said the company is "not done with" manufacturing expansions.
In this week's episode of “Podnosis,” we explore Blue Shield of California's plan to transform its pharmacy model. This includes a shift away from the traditional PBM relationship in favor of forming partnerships with five companies: Amazon Pharmacy, Abarca, Mark Cuban Cost Plus Drugs Company, CVS Caremark, and Prime Therapeutics.
This paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders.
Presented by Blue Matter, strategic consultants in the life sciences
From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level.
Uncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development.
Sponsored by: Thermo Scientific™ Production Chemicals and Services
